Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lupin
Pharma
MediLink, Takeda, Ascentage and China NMPA—Fierce Pharma Asia
BioNTech and MediLink's ADC was put on a hold. Takeda gained an option to license a CML drug. Regulators from China and the U.S. met at FDA offices.
Angus Liu
Jun 21, 2024 8:23am
Lupin names CEO for its newly announced CDMO arm
Jun 17, 2024 2:54pm
BMS-BeiGene, Sumitomo-Otsuka, AstraZeneca—Fierce Pharma Asia
Aug 4, 2023 8:50am
Lupin recalls birth control pills deemed possibly ineffective
Aug 1, 2023 8:21am
BeiGene-Novartis, Takeda, Eisai and more—Fierce Pharma Asia
Jul 14, 2023 9:20am
Lupin gets off light after FDA manufacturing plant inspection
Jul 12, 2023 2:19pm